Newly Published Data Further Support Mosaic ImmunoEngineering’s Lead Immuno-Oncology Candidate MIE-101 in Combination with OX40 Checkpoint Treatment in Melanoma
Source: BioSpace, February 2022
- Broad, durable, and systemic anti-tumor immunity observed using inCPMV with OX40 agonist antibodies
- Intratumoral inCPMV administration in combination with systemic anti-OX40 controlled the progression of the primary as well as secondary untreated tumors
- 70% of animals survived for at least 100 days post tumor challenge without development of recurrence or metastatic disease
NOVATO, CA / ACCESSWIRE / February 2, 2022 / Mosaic ImmunoEngineering, Inc. (“Mosaic" or the “Company"), (OTCQB:CPMV), a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer, today announced a new article published in the journal “Molecular Pharmaceuticals." Co-authors of the article include Mosaic co-founders Nicole F. Steinmetz, Ph.D., director of the UC San Diego Center for Nano-ImmunoEngineering, and Steven N. Fiering, Ph.D., professor of microbiology and immunology at the Geisel School of Medicine at Dartmouth University. The article, entitled, “Inactivated Cowpea Mosaic Virus in Combination with OX40 Agonist Primes Potent Antitumor Immunity in a Bilateral Melanoma Mouse Model," details broad immune activation of inactivated CPMV (termed inCPMV) and potent, systemic, and durable antitumor activity with the treatment combination in an aggressive two-tumor model of melanoma.